Entest Group Inc is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or entities. The Companyâ€™s current business plan is to seek new business opportunities or to engage in a business combination with an unidentified company. The Company has no operations and has not generated revenues.

Employees

Sector

Investment Holding Companies

More about the company

Market Cap	541K 474K 437K 409K 767K 51.02M 783K 5.25M 2.03M 25.22M 2.03M 1.99M 87.44M	P/E 2018	-0.92x	P/E 2019	12.6x
Enterprise Value	562K 493K 454K 425K 797K 53.02M 814K 5.46M 2.11M 26.2M 2.11M 2.06M 90.87M	EV / Sales 2018	-	EV / Sales 2019	-
Free-Float	98.54%	Yield 2018 *	-	Yield 2019	-

21/01/20	Entest Group, Inc. Reports Earnings Results for the First Quarter Ended November 30, 2019	CI
20/12/19	Entest Group, Inc. Reports Earnings Results for the Full Year Ended August 31, 2019	CI
15/07/19	Entest Group, Inc. Reports Earnings Results for the Third Quarter Ended May 31, 2019	CI
23/01/19	Entest Group, Inc. Reports Earnings Results for the First Quarter Ended November 30, 2018	CI
04/12/18	Entest Group, Inc. Announces Management Changes	CI
27/11/18	Peiwen Yu completed the acquisition of 48.3% stake in Entest Group, Inc. from Regen BioPharma, Inc., Bostonia Partners, Inc, Dunhill Ross Partners, Inc., Bio-Technology Partners Business Trust, David Koos and Sherman Family Trust.	CI
20/11/18	Peiwen Yu entered into an agreement to acquire 48.3% stake in Entest Group, Inc. from Regen BioPharma, Inc., Bostonia Partners, Inc, Dunhill Ross Partners, Inc., Bio-Technology Partners Business Trust, David Koos and Sherman Family Trust for $0.33 million.	CI
14/02/18	ENTB will Change its Name to ETNI	CI
27/11/15	Entest Group, Inc. Auditor Raises 'Going Concern' Doubt	CI
21/08/15	Entest Biomedical, Inc. will Change its Ticker to ENTB from ENTB.D	CI
27/07/15	Entest Biomedical, Inc. will Change its Ticker to ENTBD from ENTB	CI
16/07/14	Christine Ichim Joins Entest BioMedical Inc. as Director of Research	CI
06/03/13	Entest Biomedical Mulls Acquisitions	CI

21/01/20	ENTEST : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
07/01/20	ENTEST GROUP, INC. : Changes in Registrant's Certifying Accountant (form 8-K)	AQ
20/12/19	ENTEST : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
10/05/18	Entest Group, Inc. : Declares Property Dividend of 3,000,000 Common Shares of Zander Therapeutics Inc.	PR
13/09/17	Entest Biomedical : Zander Therapeutics, Inc. Announces Appointment of Dr. Robin Beat Gasser to Scientific Advisory Board	PR

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ENTEST GROUP, INC.	-2.86%	-.--%	-	-	9.83K
EINRIDE AB	+17.31%	-9.42%	-	-	1.07B
CENTIEL AG	-9.46%	-6.81%	+375.19%	-61.51%	773M
CHURCHILL CAPITAL CORP XI	+11.41%	+34.50%	-	-	772M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	-0.20%	-0.50%	-	-	640M
BAIN CAPITAL GSS INVESTMENT CORP.	-0.10%	+0.59%	-	-	600M
CANTOR EQUITY PARTNERS IV, INC.	-0.15%	-0.25%	-	-	592M
CHURCHILL CAPITAL CORP XII	+0.48%	+3.88%	-	-	586M
KEYSTONE ACQUISITION CORP.	-0.10%	0.00%	-	-	580M
Average	+1.81%	+2.75%	+375.19%	-61.51%	701.39M
Weighted average by Cap.	+3.55%	+2.40%	+375.19%	-61.51%

	2018	2019
Net sales	-	-
Net income	-1.48M -1.3M -1.19M -1.12M -2.1M -139M -2.14M -14.35M -5.55M -68.88M -5.55M -5.43M -239M	192K 168K 155K 145K 272K 18.08M 278K 1.86M 720K 8.93M 720K 704K 30.98M
Net Debt	19.4K 17.01K 15.68K 14.68K 27.53K 1.83M 28.1K 188K 72.92K 904K 72.85K 71.26K 3.14M	21.2K 18.59K 17.13K 16.04K 30.08K 2M 30.7K 206K 79.68K 988K 79.59K 77.86K 3.43M

Entest Group, Inc. Stock Other OTC

Stocks

ETNI

US29383T3005

Investment Holding Companies

Valuation: Entest Group, Inc.

Latest news : Entest Group, Inc.

Press Releases: Entest Group, Inc.

Quotes and Performance

Managers and Directors: Entest Group, Inc.

Shell Companies

Financials

Company Profile